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We compared the caspofungin (CAS) susceptibility testing results generated by the disk diffusion (DD) assay
with the results of the Clinical and Laboratory Standards Institute (CLSI) broth microdilution (BD) reference
method for 106 yeast isolates. The isolates represented 11 different fungal species, including Candida albicans
(n  50), C. parapsilosis (n  10), C. glabrata (n  10), C. tropicalis (n  10), C. guillermondii (n  6), C. rugosa
(n  5), C. krusei (n  5), C. kefyr (n  2), C. pelliculosa (n  2), Saccharomyces cerevisiae (n  3), and
Geotrichum candidum (n  3). The DD assay was performed in supplemented Mueller-Hinton agar with CAS,
which was tested at concentrations of 2, 10, and 25 g per disk. MICs and inhibition zone diameters were
evaluated at 24 and 48 h. In general, the results obtained by the DD assay correlated well with those obtained
by the BD method. In particular, a significant correlation between methods was observed when CAS was used
at concentration of 2 g/disk at a reading time of either 24 or 48 h.
The increase in the rates of fungal infections, the changes in
their epidemiology, the emergence of resistance, and the tox-
icities that some of the commercial antifungal drugs display
have resulted in the need for an expanded arsenal of antifungal
drugs. Echinocandins represent a new class of antifungal
agents that act by inhibiting the synthesis of 1,3--D-glucan, a
key step in fungal cell wall biosynthesis (10). Caspofungin
acetate (CAS) is a water-soluble, potent echinocandin with
activity against a number of clinically important fungi. Al-
though many authors investigated the activity of CAS against
clinical isolates of fungi (1–3, 16), caution should be used
before drawing clinical conclusions about the susceptibility re-
sults (5, 9). In addition, the MIC for CAS determined by the
reference broth microdilution (BD) method can be altered
greatly by changes in assay conditions, including the test for-
mat, the time of reading, as well as the definition of the end
point (5).
Agar-based antifungal susceptibility testing, such as the disk
diffusion (DD) method, can be an alternative that has a lower
cost and the need for a reduced amount of labor compared
with those required for the reference BD assay, although the
results obtained by the DD assay can be plagued by the same
variables that alter the MICs obtained by the BD method. In
addition, the DD assay does not generate an MIC of the drug
but generates only a zone of inhibition. In the last few years,
several investigators compared the results of triazole MICs for
yeasts and filamentous fungi obtained by the BD and the DD
methods (4, 7, 8, 11, 13, 17). Few data are still available for
echinocandin drugs. Therefore, in this study we compared the
CAS susceptibility results obtained by the DD method with
those obtained by the BD method for 106 yeast isolates. Three
different concentrations of CAS were investigated to find the
best correlation between the two methods.
MATERIALS AND METHODS
Organisms. A total of 106 clinical yeast isolates were tested. The collection
included Candida albicans (n 50), C. parapsilosis (n 10), C. glabrata (n 10),
C. tropicalis (n  10), C. guillermondii (n  6), C. rugosa (n  5), C. krusei (n 
5), C. kefyr (n  2), C. pelliculosa (n  2), Saccharomyces cerevisiae (n  3), and
Geotrichum candidum (n  3). The isolates were recovered from blood;
abscesses; and the gastrointestinal, respiratory, and urinary tracts.
Antifungal agents. A standard antifungal powder of CAS (Merck Co., White-
house Station, PA) was obtained from the manufacturer. Stock solutions were
prepared in water. Serial twofold dilutions were prepared exactly as outlined in
CLSI (formerly NCCLS) document M27-A2 (14). Final dilutions were made in
RPMI 1640 medium (Sigma, Milan, Italy) buffered to pH 7 with 0.165 M mor-
pholinopropanesulfonic acid buffer (Sigma). Aliquots of 0.1 ml of CAS at a 2
concentration were placed into the wells of plastic microdilution trays, which
were then sealed and stored at 70°C until they were used, which was within 7
days.
BD method. BD testing was performed in accordance with the guidelines of
the CLSI M27-A2 document by using the spectrophotometric method for inoc-
ulum preparation, an inoculum concentration of 1.5 ( 1.0)  103 cells/ml, and
RPMI 1640 medium (14). A total of 0.1 ml of fungal inoculum was added to each
well of the microdilution trays. The final concentrations of CAS were 0.008 to 4.0
g/ml. The trays were incubated at 35°C, and MICs were read at 24 and 48 h.
Drug-free and fungus-free controls were included. Following incubation, the
wells were examined and the growth in each well was compared to that in the
growth control well. The MIC of CAS was defined as the minimum concentration
(in micrograms per milliliter) of antifungal agent that provided an 50% reduc-
tion in growth compared to the growth in the control well (15, 16).
DD assay. Blank disks of 6.3 mm in diameter (Becton Dickinson Microbiology
Systems, Cockeysville, MD) were impregnated with 20 l of CAS suspensions,
resulting in final concentrations of 2, 10, and 25 g/disk. The disks were allowed
to dry at room temperature. Testing was performed on Mueller-Hinton agar
plates supplemented with 2% glucose and 0.5 g of methylene blue per ml. For
each isolate, duplicate plates were inoculated by dipping two sterile cotton swabs
into a 0.5 McFarland suspension and streaking the plate surface in three direc-
tions. After the plate was allowed to dry for 20 min, disks with each concentration
were plated in duplicate to test each isolate and the plates were incubated at
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35°C. Zone diameters (in millimeters) for the zone of complete inhibition were
determined after 24 and 48 h of incubation. The zone edges were easily defined
as the point of complete inhibition of growth. To assess the reproducibility of the
methodology, the inhibition zone diameters were obtained on two different days
for 19 of the 106 fungi evaluated, including 8 isolates (4 C. albicans strains, 3
non-C. albicans strains, and 1 S. cerevisiae strain) with MICs 2.0 g/ml.
QC. Quality control (QC) was performed in accordance with the guidelines in
CLSI documents M27-A2 and M44-A by using C. krusei ATCC 6258 and C.
parapsilosis ATCC 22019 (6, 14). The CLSI QC isolates were tested each time
that a set of isolates was evaluated by the two procedures.
Interpretation of results. The degree of correlation between the MICs and the
disk diffusion zone diameters was analyzed by use of Pearson’s correlation
coefficient. A linear relationship was assessed by using least-squares regression,
weighted by the number of strains. For comparative evaluation of the BD and
DD methods, the arithmetic means (AMs) and the ranges of the MICs and the
AMs and the ranges of the inhibition zone diameters were calculated for each
species.
RESULTS AND DISCUSSION
The median CAS MICs for C. kusei ATCC 6258 and C.
parapsilosis ATCC 22019 were 2.0 g/ml and 1.0 g/ml, re-
spectively (18). Table 1 summarizes the results of the BD and
DD assays obtained at 24 and 48 h. The CAS MICs for C.
TABLE 1. In vitro activity of CAS against 106 fungal isolates
Species
(no. of strains)
CAS concn
(g/disk)
Susceptibility testing result by DD
assay (mm) at: Susceptibility testing result by CLSI method (g/ml) at:
24 h 48 h 24 h 48 h
Range AM Range AM Range AM Range AM
C. albicans (50) 2 9–16 12.58 9–16 12.86 0.06–4 0.66 0.06–4 0.86
10 18–27 20.58 18–27 20.80
25 17–25 22.98 20–28 23.20
C. parapsilosis (10) 2 9–15 11.10 9–15 11.30 0.5–4 1.12 0.5–4 2.150
10 17–23 20.00 17–23 20.10
25 20–26 22.50 20–26 22.60
C. glabrata (10) 2 9–20 13.00 9–20 13.09 0.125–2 0.54 0.25–2 1.20
10 17–24 20.73 18–24 20.82
25 20–26 23.55 20–28 23.73
C. tropicalis (10) 2 10–13 12.00 10–13 12.18 0.125–0.5 0.27 0.125–1 0.54
10 16–22 19.18 17–22 19.36
25 18–26 21.64 18–25 21.64
C. guillermondii (6) 2 10–14 11.67 10–14 11.67 0.125–1 0.35 0.25–2 0.71
10 18–20 19.33 18–20 19.33
25 21–23 21.83 21–23 21.83
C. rugosa (5) 2 9–18 15.00 12–18 15.60 0.125–0.25 0.17 0.25–0.5 0.40
10 20–23 21.80 20–23 21.80
25 24–26 25.20 24–26 25.20
C. krusei (5) 2 9–15 12.80 12–18 15.60 0.125–1 0.575 0.25–0.5 0.40
10 9–20 17.80 20–23 21.80
25 20–22 21.60 24–26 25.20
C. kefyr (2) 2 15–17 16.00 16–17 16.50 0.06–0.125 0.09 0.125–0.25 0.18
10 21 21 21 21
25 24–25 24.50 24–25 24.50
C. pelliculosa (2) 2 12–17 14.50 12–17 14.50 0.06–0.125 0.09 0.125–0.5 0.313
10 21 21 21 21
25 24–25 24.50 24–25 24.50
Others (6) 2 7–15 11.50 7–15 11.50 0.06–4 2.82 0.25–4 2.96
10 8–22 16.83 8–22 16.83
25 10–26 19.16 10–26 19.50
TABLE 2. Correlation between BD and DD methods for CAS
susceptibility testing
Time of
reading
Species (no. of
strains)
CASa concn
(g/disk)
Pearson’s
correlation (r)
24 h C. albicans (50) 2 0.383
10 0.130
25 0.354
Non-C. albicans
species (50)
2 0.333
10 0.118
25 0.184
Others (6) 2 0.925
10 0.993
25 0.988
48 h C. albicans (50) 2 0.416
10 0.196
25 0.129
Non-C. albicans
species (50)
2 0.417
10 0.212
25 0.187
Others (6) 2 0.938
10 0.997
25 0.991
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albicans isolates ranged from 0.06 to4.0 g/ml at either 24 or
48 h. The CAS MICs for Candida other than C. albicans and
for the other fungal isolates ranged from 0.06 to 4.0 g/ml at
24 h and from 0.125 to 4.0 g/ml at 48 h. In general, the halo
diameters obtained with the disks embedded with the highest
CAS concentration were larger than those produced with the
lower concentrations. A tendency toward slightly larger zones
after 48 h of incubation was noted for the majority of the
isolates tested. The biggest difference between the first- and
second-day readings was observed for C. krusei isolates.
Table 2 summarizes the correlation between the methodol-
ogies. The best correlation between the methods was obtained
by the use of CAS at a concentration of 2.0 g/disk at either
24 h or 48 h of reading for C. albicans (r  0.383 at 24 h and
r0.416 at 48 h) and for non-C. albicans species (r0.333
at 24 h and r  0.417 at 48 h). With the exception of sus-
FIG. 1. Regression analysis for CAS susceptibility values of C.
albicans isolates (n  50) correlating the 24-h zones of inhibition (mm)
determined with Mueller-Hinton agar plates with the 24-h MICs de-
termined by the CLSI BD method (g/ml). The line of best fit is
shown, and the regression statistics gave a Pearson’s r value of 0.383.
The numbers in the figure are the numbers of strains that correlate
with each value.
FIG. 2. Regression analysis for CAS susceptibility values of C.
albicans isolates (n  50) correlating the 48-h zones of inhibition (mm)
determined with Mueller-Hinton agar plates with the 48-h MICs de-
termined by the CLSI broth dilution method (g/ml). The line of best
fit is shown, and the regression statistics gave a Pearson’s r value of
0.416. The numbers in the figure are the numbers of strains that
correlate with each value.
FIG. 3. Regression analysis for CAS susceptibility values of non-
Candida albicans isolates (n  50) correlating the 24-h zones of inhi-
bition (mm) determined with Mueller-Hinton agar plates with the 24-h
MICs determined by the CLSI broth dilution method (g/ml). The line
of best fit is shown, and the regression statistics gave a Pearson’s r value
of 0.333. The numbers in the figure are the numbers of strains that
correlate with each value.
FIG. 4. Regression analysis for CAS susceptibility values of non-
Candida albicans isolates (n  50) correlating the 48-h zones of inhi-
bition (mm) determined with Mueller-Hinton agar plates with the 48-h
MICs determined by the CLSI broth dilution method (g/ml). The line
of best fit is shown, and the regression statistics gave a Pearson’s r value
of 0.417. The numbers in the figure are the numbers of strains that
correlate with each value.
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ceptibility testing for the isolates belonging to genera other
than Candida, the results obtained with CAS at 10 and 25 g
did not correlate significantly with the results obtained by the
BD method.
Figures 1 to 4 show the isolate-by-isolate relationship be-
tween the log10 MIC and the inhibition zones produced on
agar plates by 2-g disks after 24 and 48 h of incubation. For
most organisms tested, the more susceptible that the organism
was by the BD method, the greater the inhibition zone that was
produced on agar. On the basis of the findings presented in
previous reports, we grouped the isolates with MICs of 1
g/ml as being susceptible and those with MICs of2 g/ml as
being resistant (15, 16).
Table 3 summarizes the agreement between the two meth-
ods. In particular, among the Candida isolates showing CAS
MICs 1.0 g/ml at 24 h, 75.2% (76.1% for C. albicans and
74.4% for the other Candida spp.) produced halo diameters
that ranged from 12 to 16 mm. Similarly, among those isolates
showing CAS MICs 2.0 g/ml, 100% of the strains showed
inhibition zone diameters that ranged from 9 to 11 mm. At the
second-day reading, the proportions of C. albicans and non-C.
albicans isolates with MICs 1.0 g/ml and inhibition zones
12 mm increased to 86.4% and 75.7%, respectively.
Since the clinical laboratory needs easy, reliable, and non-
time-consuming alternative methods for the determination of
the MICs of antifungal agents, we investigated a DD proce-
dure as a method for testing the activity of CAS against clinical
fungal isolates. We examined three different concentrations of
the echinocandin and found that the best correlation with the
BD results was obtained by using disks containing 2 g of CAS.
Our data agree with those previously reported by Lozano-Chiu
et al. (12). Those authors found that a final CAS concentration
of 2.5 g/disk yielded the best range of zone diameters of all
the concentrations tested. Our data seem to indicate a greater
correlation between the two methodologies when CAS is used
at 2 g/disk against Candida spp. on either the first- or the
second-day reading. Further studies involving clinical isolates
obtained from patients with well-known clinical outcomes are
warranted to further elucidate this important technical issue.
In general, our data show that this agar-based method hold
promise as a simple and reliable method for determining the
susceptibilities of Candida spp. to CAS.
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